Background: In dogs with protein-losing enteropathy (PLE), data on the clinical characteristics of food-responsive PLE (FR-PLE) remain scarce. Objective: To determine the clinical characteristics of FR-PLE in dogs responsive to ultralow-fat diet (ULFD) management. Animals: Thirty-three dogs diagnosed with PLE based on standard diagnostic criteria. Methods: Retrospective review of medical records. Clinical findings were compared between dogs with FR-PLE (FR-PLE group) and those with immunosuppressantresponsive PLE (IR-PLE) or nonresponsive PLE (NR-PLE) (IR/NR-PLE group). The area under the curve (AUC) of a receiver operating characteristic curve was used to evaluate the ability of factors to differentiate the FR-PLE and IR/NR-PLE groups. Survival time was compared between the FR-PLE and IR/NR-PLE groups.
| INTRODUCTION
Protein-losing enteropathy (PLE) is a syndrome characterized by excessive loss of albumin from the gut mucosa. 1 Common diseases related to PLE in dogs include chronic enteritis, infectious diseases, intestinal lymphoma and intestinal lymphangiectasia (IL), and the clinical presentations of these diseases are similar. 1 Although histopathological evaluation of the gastrointestinal tract by endoscopic or full-thickness biopsy generally is recommended to determine the cause of PLE and select appropriate treatments, therapeutic trials including dietary treatment are applied in some cases. 2, 3 These cases may include dogs with severe hypoalbuminemia and expected anesthetic risk.
There is limited information on the effect of diet on dogs with PLE because these dogs typically show severe clinical signs and are expected to have a guarded prognosis with rapid progression. 4, 5 An exception is management using a fat-restricted diet for dogs with primary IL. 3, 4, 6, 7 A fat-restricted diet, especially homemade ultralow-fat diet (ULFD), has been recommended for dogs with primary IL for many years, and it has been believed to decrease intestinal lymphatic pressure by decreasing fat absorption from intestinal mucosa. 6 The fat content of an ULFD made from chicken breast and white potato is 0.35 g/100 kcal, 7 whereas that of a conventional low-fat dry diet is approximately 2 g/100 kcal. 8 A study showed that dogs with IL refractory to prednisolone or dependent on high-dose prednisolone exhibited improvements in total protein and albumin concentrations and clinical signs after an ULFD were introduced. 7 Another study indicated that an ULFD (fat content, 0.31 g/100 kcal) or a low-fat diet (fat content, 1.86-2.56 g/100 kcal) as the sole treatment is a potential treatment strategy in Yorkshire Terriers with suspected PLE. 3 Although a low-fat diet alone has been shown to be effective for some dogs with PLE, 3 the effect of ULFD generally is considered to be better than that of a low-fat diet for dogs with IL because of its strict fat restriction and high palatability. 6, 7 These data indicated that dietary management, specifically an ULFD, is a preferable treatment choice for dogs with PLE. 4 Recently, dogs with PLE that respond to dietary interventions have been classified as having food-responsive PLE (FR-PLE). 4 Differentiating FR-PLE from other types of PLE, such as immunosuppressant-responsive PLE (IR-PLE) or nonresponsive PLE (NR-PLE), 4 may be clinically important, especially in terms of initiating dietary management. Dietary management has several advantages, including elimination of unnecessary use of glucocorticoids or other immunosuppressants, which are associated with various adverse effects. Nevertheless, the decision to carry out dietary intervention for PLE is difficult because of the scarcity of information available on the clinical characteristics of FR-PLE in dogs and the unpredictable response of PLE patients to dietary management. Therefore, the purpose of our study was to clarify the clinical characteristics of dogs with FR-PLE in comparison with those of dogs with IR-PLE or NR-PLE. The hypothesis was that dogs with less severe clinical signs would be responsive to an ULFD and that, among dogs with PLE, prognoses would be better in those with FR-PLE than in those with IR-PLE or NR-PLE.
| MATERIALS AND METHODS

| Study design
A retrospective review of the medical records of dogs with PLE was conducted between June 2013 and July 2018 in a veterinary teaching hospital.
| Cases
The medical records of all dogs that underwent upper gastrointestinal endoscopy with or without lower gastrointestinal endoscopy in our hospital were reviewed. The inclusion criterion for our study was the diagnosis of PLE. The criteria for the diagnosis of PLE were hypoalbuminemia (<2.6 g/dL) with no evidence of other causes of hypoalbuminemia based on physical examination, CBC, serum biochemistry, fecal examination, urinalysis, radiography, and abdominal ultrasonography. Dogs with concurrent disorders were excluded from the study. Dogs lost to follow-up within 2 weeks of admission also were excluded from the study. Dogs diagnosed with intestinal neoplasia, such as lymphoma based on histopathology, also were excluded.
Informed written consent from all dog owners was obtained for data collection and usage in the study.
The definitive diagnoses of the dogs with PLE were determined based on the treatment response, and the identified dogs were divided into 2 groups: dogs with FR-PLE (FR-PLE group) and dogs with IR-PLE or NR-PLE (IR/NR-PLE group). Dogs that responded to ULFD as an initial treatment were placed in the FR-PLE group. The response to ULFD was evaluated based on clinical signs according to previously established scoring systems, which include the canine inflammatory bowel disease activity index (CIBDAI) 9 and the canine chronic enteropathy clinical activity index (CCECAI), 10 and plasma albumin concentration (ALB). The CIBDAI and CCECAI scores were retrospectively calculated based on individual criteria extracted from the medical records. If dogs showed improvement in the CIBDAI (≤3) or CCECAI (≤3) score after the ULFD intervention, they were considered to have FR-PLE. For dogs with CIBDAI (≤3) and CCECAI (≤3) score on the initial visit, improvements in the ALB score based on the CCECAI scoring system 10 were considered to be responsive (FR-PLE).
Dogs with FR-PLE were further divided into complete responders and partial responders based on the ALB or a requirement for additional prednisolone during the clinical course. The complete responders were defined as those that achieved normal ALB (≥2.6 g/dL) and did not require additional prednisolone, whereas partial responders were defined as those with partial improvement in ALB (not reaching 2.6 g/dL) or requirement for additional prednisolone during the clinical course. Other dogs were classified as IR-PLE or NR-PLE according to their response to immunosuppressant drugs.
The ULFD was formulated based on a previous study. 7 The formula included 1 part chicken breast without skin and 2 parts white potato without skin or rice (all of the ingredients were boiled). When dogs showed improvement in ALB after initiation of the ULFD, a lowfat (Royal Canin GI low fat with fat content of 2.03 g/100 kcal or Hill's i/d low fat with fat content of 2.3 g/100 kcal) or hydrolyzed (Royal Canin Anallergenic with fat content of 4.25 g/100 kcal) dry canine diet was added gradually to the ULFD to prevent secondary nutritional hyperparathyroidism and deficiencies in vitamins and minerals from the long-term feeding of the ULFD.
| Histopathology
Tissue samples were obtained from the stomach, proximal duodenum, and distal duodenum for all dogs and from the ileum for some dogs (n = 11) by endoscopy. Ileal tissue collection was performed by attending clinicians on the basis of the clinical signs and ultrasonographic findings in each case. During endoscopy, at least 6 mucosal samples were collected from each previously noted segment of the gastrointestinal tract. 11 Histopathological examination was conducted by an American College of Veterinary Pathologists board-certified pathologist using a scoring system according to histopathologic standards established in the World Small Animal Veterinary Association (WSAVA) guidelines. 12 Polymerase chain reaction for antigen receptor gene rearrangement (PARR) was performed based on clinical findings and histopathological analysis on a case by case basis. Immunohistochemistry was not performed in any cases in our study.
| Data collection
The following information was collected from the medical records: Ultrasonographic images of the small intestine were reviewed for each case, and the following findings were extracted: the presence of hyperechoic intestinal mucosal striations defined as multiple clear intramucosal hyperechoic lines, mesenteric lymphadenopathy defined as the size of a mesenteric lymph node >5 mm, and loss of layering defined as indistinguishable intestinal layers. 13 The presence of ascites also was evaluated.
Endoscopic scores were retrospectively evaluated by using still images based on the previously described simple endoscopic scoring system in which the absence (score 0) or presence (score 1) of friability, granularity, erosions, and lymphatic dilatation of the duodenum was assessed. 14 These images were evaluated by an experienced endoscopist, and scores were summarized with maximum scores of 4. All statistical analyses were conducted by using EZR, which is a graphical user interface for R. 15 P values <.05 were considered statistically significant (P < .004 after Bonferroni correction).
| Statistical analysis
| RESULTS
A flowchart of the inclusion criteria for the study is shown in Figure 1 . Overall, 12 dogs were considered complete responders in that they achieved normal ALB and did not require additional prednisolone, whereas the other 11 dogs were considered partial responders in that they exhibited partial improvement in ALB or required adjunctive prednisolone treatment. The median dosage of prednisolone for partial responders was 1.1 mg/kg/day (range, 0.73-2.0 mg/kg/day).
Among the dogs in the FR-PLE group, 7 previously participated in dietary trials that had included a low-fat diet (3 dogs), a hydrolyzed diet (1 dog), a novel antigen diet (1 dog), a high-fiber diet (1 dog), or a combination diet (1 dog). Seven dogs were treated with F I G U R E 1 A flowchart of the case descriptions. FR-PLE, food-responsive PLE; IR-PLE, immunosuppressant-responsive PLE; NR-PLE, nonresponsive PLE; PLE, protein-losing enteropathy prednisolone (range, 0.40-2.4 mg/kg/day) before referral to our hospital, but this treatment resulted in no improvement. Prednisolone was completely withdrawn in 4 of these dogs and tapered in 1 dog by the final follow-up after they were fed the ULFD. Two dogs required treatment with a higher dosage of prednisolone (from 0.40 to 0.93 mg/kg and from 0.5 to 1.1 mg/kg) after achieving a partial response with the ULFD. Based on histopathology, 17 of the 23 dogs showed various degrees of lacteal dilatation, whereas the other 6 dogs did not show lacteal dilatation (Figure 1 ).
The other dogs in the study included 6 with IR-PLE and 4 with NR-PLE. Four dogs did not respond to ULFD management and were histopathologically diagnosed with lymphoplasmacytic enteritis with lymphangiectasia. Three of these 4 dogs responded to immunosuppressant treatment (prednisolone 1.1 mg/kg/day, prednisolone 1.2 mg/kg/day, and prednisolone 1.77 mg/kg/day with cyclosporine 4.2 mg/kg/day). The ULFD was not used in 6 dogs, and immunosuppressant treatment was immediately commenced in these dogs. Two of these 6 dogs previously underwent dietary trials that included a low-fat diet (1 dog) or a digestive support diet (1 dog). These 6 dogs were histopathologically diagnosed with lymphoplasmacytic enteritis with lymphangiectasia (4 dogs) or lymphoplasmacytic enteritis (2 dogs Figure 3 ). However, no significant difference was found in CCECAI scores between the complete responders (median score, 5; range, 2-10) and partial responders (median score, 5; range, 2-10; P = 1; Figure 4 ) and no significant difference was found in CIBDAI scores between complete responders (median score, 4; range, 0-8) and partial responders (median score, 2;
range, 0-5; P = .23; Figure 4 ), nor in age, weight, ALB, GLB, CRP, and ultrasonographic findings (P > .05).
| DISCUSSION
Our results suggest that age and CIBDAI and CCECAI scores at the time of diagnosis of PLE may be useful for predicting patient responsiveness to an ULFD. In our study, the dogs with FR-PLE had a more favorable prognosis than those with IR-PLE or NR-PLE.
We attempted to evaluate clinical findings in FR-PLE in dogs by including all dogs that were diagnosed with PLE in our hospital and that also underwent endoscopic biopsies. Although some dogs in the study did not have normal ALB or required adjunctive prednisolone after achieving a partial response to ULFD, we classified these dogs as FR-PLE (partial responders) rather than IR-PLE because a partial response to a dietary intervention may benefit dogs with PLE in terms of its potentially sparing effect on immunosuppressant drug use.
The sparing effect of the dietary intervention may result in a decrease in the dose of prednisolone required to achieve a complete response and eliminate the concomitant use of other immunosuppressants. In fact, no dogs with partial response in our study required the concomitant use of other immunosuppressants to achieve normal ALB concentrations.
Our results show that CCECAI scores were significantly lower in the FR-PLE group than in the IR/NR-PLE group. According to the ROC analysis, CCECAI scores are useful for discriminating between the FR-PLE and IR/NR-PLE groups. In addition, among the 27 dogs subjected to dietary interventions, CCECAI scores were significantly lower in responders than in nonresponders, indicating that CCECAI scores are a possible indicator that predicts the response to an ULFD in dogs with PLE. However, only 4 dogs in our study were nonresponders. These results support the idea that dietary intervention may be beneficial for dogs with PLE if the dogs have less severe clinical signs. 4 Based on our results and those of a previous study, 3 at least 2 weeks of a dietary trial can be recommended in these cases.
On the other hand, CCECAI scores were not significantly different between complete responders and partial responders, indicating that differentiating these populations using CCECAI scores would be difficult. However, in our study, a complete responder was defined as a dog that achieved and maintained normal ALB (>2.6 g/dL). This is a relatively strict criterion because an improvement in CCECAI score (CCECAI ≤3) without normal ALB can be considered a treatment success. 3 In this population of dogs with PLE, the goal of treatment was to achieve normal ALB, and prednisolone therefore was commonly used for dogs with even mild hypoalbuminemia. It is not clear whether these dogs actually required the adjunctive prednisolone. In fact, 2 partial responders were clinically controlled by the final follow-up (212 and 1449 days) without prednisolone (ALB concentrations at the final follow-up were 2.1 and 2.4 g/dL, respectively). Moreover, 3 dogs initially had achieved a complete response with ULFD treatment but showed recurrence of hypoalbuminemia when the percentage of dry food was increased, prompting adjunctive prednisolone treatment.
We chose to administer adjunctive prednisolone treatment in these 3 dogs instead of using a 100% ULFD in terms of the nutritional disadvantage associated with a 100% ULFD. These dogs possibly could have been managed using a nutritionally balanced 100% ULFD that has been suggested previously. 6 Interestingly, the median CIBDAI score even before dietary intervention in the FR-PLE group indicated clinically unimportant disease, suggesting that this clinical score is not useful in some cases in dogs with PLE. In fact, 1 dog was considered to have clinically unimportant disease by CIBDAI (score 0) but moderate disease by CCECAI (score 6).
Therefore, it may be important to calculate both CIBDAI and CCECAI scores for dogs with PLE.
Our results also indicated age as a useful indicator for predicting patient responsiveness to an ULFD. A previous study showed that dogs diagnosed with IL tend to be younger than those with chronic enteropathy, small cell lymphoma, or large cell lymphoma. 5 Considering that dogs with primary IL tend to be young and responsive to ULFD, 5,7 we F I G U R E 4 Comparison of CIBDAI and CCECAI scores between complete responders (n = 12) and partial responders (n = 11) to ULFD management. There was no significant difference in CIBDAI and CCECAI scores between the complete responders and partial responders. No dogs among the responders showed loss of intestinal layering in our study, which is similar to a previous study in which no dogs with intestinal mucosal striations showed loss of intestinal layering, except 1 dog with a lipogranuloma. 13 These findings suggested that mesenteric lymphadenopathy and loss of intestinal layering are not common findings in dogs with FR-PLE or primary IL.
Compared to the IR/NR-PLE group, the FR-PLE group had longer survival times, indicating that differentiating between these 2 groups of dogs with PLE based on responsiveness to the ULFD is important in predicting the prognosis. Because the FR-PLE group had significantly lower CIBDAI and CCECAI scores than those found in the IR/NR-PLE group, the longer survival time of the FR-PLE group may be attributed to the severity of the disease, which has been shown to be associated with prognosis in dogs with PLE. 5, 21 In addition, other factors, such as body weight, BUN, ALB, and PARR could be associated with survival time. 5, 8, [22] [23] [24] [25] [26] Therefore, further study is needed to evaluate the effect of ULFD itself on the prognosis of dogs with PLE.
The ALB of the dogs in our study was not significantly different between the groups despite the significant difference between the survival times. Previous studies performed in dogs with PLE showed that ALB is not associated with survival. 5, 22, 24 However, other studies that included dogs with chronic enteropathy or Yorkshire Terriers with PLE have reported that hypoalbuminemia is related to a poor prognosis. 10, 25, 27 This difference may be attributed to differences in the inclusion criteria. Based on these results and previous studies, ALB alone does not seem to predict prognosis of different groups of dogs with PLE.
Our study had several limitations. First, we could include only a relatively small number of cases because the study was conducted at a single center. Therefore, further evaluation using a larger number of cases is necessary to verify these findings. Second, because of the retrospective study design, diagnostic procedures and treatment choices differed in each case. The CIBDAI and CCECAI scores were calculated retrospectively, possibly resulting in some bias. Because ileal biopsies were performed in only 33% of dogs in our study, disease processes in the ileum different from those in the duodenum (including localized lymphoma) could not be completely ruled out. Furthermore, lymphoma was diagnosed based on histopathology and not immunohistochemistry and PARR in our study. Considering the limitations of histopathology for the diagnosis of lymphoma, 28 lymphoma could not be completely excluded especially in 3 dogs that were PARR positive, although 51% of dogs with chronic enteritis showed positive results for PARR in a previous study. 29 In addition, functional biomarkers for enteropathy in dogs, such as fecal and serum concentrations of alpha-1 proteinase inhibitor, folate, and cobalamin, 30 which are possibly useful for determining responsiveness to ULFD, were not measured in most dogs in our study. Serum cobalamin concentrations were measured in only 2 dogs (180 pg/mL in 1 dog with FR-PLE and 195 pg/mL for the other dog with IR-PLE; reference interval, 230-900 pg/mL). Moreover, not all dogs underwent ULFD management in our study, and therefore the responsiveness to the ULFD for 6 dogs in the IR/NR-PLE group was not determined. These dogs might have responded to the ULFD if given concurrently with symptomatic treatment such as antiemetic medication or an ULFD formulation designed for assisted feeding. Because of the retrospective design, initiating dietary intervention in all cases was difficult in our study. A prospective and multicenter study to confirm the effectiveness of an ULFD targeting dogs with PLE is needed. Finally, serum bile acid concentrations were not measured in all dogs in the study, but hepatic dysfunction was considered unlikely in these dogs based on routine serum biochemical analysis (ie, normal glucose, BUN, and total bilirubin concentrations and normal liver enzyme activity). Likewise, because both the urine protein: creatinine ratio and urine dipstick protein test were not available for 2 dogs in our study, protein-losing nephropathy was not completely ruled out for these dogs. In addition, because serum cortisol concentrations were measured in only 2 dogs (basal cortisol concentrations of 3 and 4.1 μg/dL), atypical hypoadrenocorticism could not be fully excluded for other dogs, although other findings, including abdominal ultrasonography, did not support a diagnosis of hypoadrenocorticism in any of the dogs. However, abdominal ultrasonography is not completely sensitive diagnostically for hypoadrenocorticism. [31] [32] [33] This is important especially among dogs that respond to prednisolone treatment. Thus, the coexistence of hepatic dysfunction, protein-losing nephropathy, and atypical hypoadrenocorticism was not completely ruled out in this population of dogs.
In conclusion, an ULFD may be beneficial for dogs with PLE. Dogs that respond to ULFD management and are diagnosed with FR-PLE are expected to have a favorable prognosis. Age and clinical scores, such as CCECAI, may be useful for differentiating FR-PLE from IR-PLE or NR-PLE. Further validation of our findings should be carried out in a prospective study including a larger number of dogs.
